Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, Sermorelin is used as a diagnostic agent for assessing GH secretory capacity and as a research tool or off-label therapy to increase endogenous GH in GH-deficient or age-related contexts1727.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, Sermorelin is a synthetic 29-amino-acid peptide identical to the 1–29 N-terminal fragment of human GHRH that stimulates GH synthesis and secretion by binding pituitary GHRH receptors1727120.
FOXO4-DRI
FOXO4
Sermorelin
GHRH
FOXO4-DRI and Sermorelin are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Aging and longevity contexts, while FOXO4-DRI is more of a senolytic peptide and Sermorelin is better described as a hormone peptide. Their biological logic is quite different: FOXO4-DRI is a protein interaction inhibitor, whereas Sermorelin is a receptor agonist. FOXO4-DRI has a more synthetic design origin, while Sermorelin is closer to synthetic analog background and their development context also differs, with FOXO4-DRI in Preclinical development while Sermorelin is approved. FOXO4-DRI carries retro-inverso isomerization features, while Sermorelin instead reflects amidation changes, while their sequence patterns also diverge, with FOXO4-DRI showing protein-mimetic sequence features and Sermorelin showing alpha-helical domain features.
No related articles are linked to these peptides yet.